Patents Assigned to Spherics, Inc.
-
Publication number: 20110086095Abstract: Polymers and compositions, collectively “bioadhesive materials”, with improved bioadhesive properties have been developed. One or more compounds comprising: a) an aromatic moiety comprising two or more hydroxyl substituents, methoxy substituents, substituents hydrolyzable to hydroxyl substituents, or a combination thereof, and b) a primary or secondary amino moiety are either covalently attached to a polymer or are physically mixed with a polymer to form a bioadhesive material. These bioadhesive materials can be used, for example, to fabricate new drug delivery or diagnostic systems with increased residence time at tissue surfaces, and consequently increase the bioavailability of a drug or a diagnostic agent.Type: ApplicationFiled: June 23, 2006Publication date: April 14, 2011Applicant: Spherics, IncInventors: Jules Jacob, Avinash Nangia, James Yeh, Vijayalakshmi Ramanan
-
Publication number: 20100226855Abstract: The present invention relates to a drug delivery system, in which a drug containing core, either alone or coated with a rate controlling membrane system, is enveloped on its circumference by an optionally bioadhesive coating, thereby yielding a monolithic system that allows for drug release in a regulated manner.Type: ApplicationFiled: March 2, 2007Publication date: September 9, 2010Applicant: Spherics, Inc.Inventors: Avinash Nangia, Jules Jacob, Peyman Moslemy, Dinesh K. Haswani
-
Publication number: 20080299204Abstract: The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual.Type: ApplicationFiled: June 23, 2006Publication date: December 4, 2008Applicant: Spherics, Inc.Inventors: Avinash Nangia, Jules Jacob, James Yeh, Peyman Moslemy, Daya D. Verma, Dinesh K. Haswani, Ze'ev Shaked
-
Publication number: 20080260824Abstract: The present invention relates to a bioadhesive drug delivery system (BIOadhesive Rate controlled Oral Dosage (BIOROD) formulation) in which a drug containing core either alone or coated with a rate controlling membrane system is enveloped on its circumference by a bioadhesive coating, thereby yielding a monolithic system that allows for drug release in a regulated manner. Also described herein are polymers with improved bioadhesive properties and methods for improving bioadhesion of polymers.Type: ApplicationFiled: August 29, 2005Publication date: October 23, 2008Applicant: Spherics, Inc.Inventors: Avinash Nangia, Jules Jacob, Peyman Moslemy
-
Publication number: 20080131492Abstract: The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual.Type: ApplicationFiled: June 22, 2007Publication date: June 5, 2008Applicant: Spherics, Inc.Inventors: Avinash Nangia, Jules Jacob, James Yeh, Peyman Moslemy, Daya D. Verma, Dinesh K. Haswani, Ze'ev Shaked
-
Publication number: 20080085306Abstract: The present invention is directed to pharmaceutical compositions that allow for once-daily or alternate day dosage forms of topiramate. The proposed delayed/extended release single dosage form is equivalent to the immediate-release multiple dose daily regimen, and upon administration, provides steady state blood levels of topiramate. Formulations with increased bioavailability and improved pharmacokinetics are disclosed. A once-a-day administration of topiramate is advantageous over the multiple dose regimen both in terms of patient compliance and reduced adverse events, thus providing better treatment of the conditions for which the topiramate is indicated.Type: ApplicationFiled: August 31, 2007Publication date: April 10, 2008Applicant: Spherics, Inc.Inventors: Avinash Nangia, Daya Verma, Jules Jacob
-
Publication number: 20070148238Abstract: The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual.Type: ApplicationFiled: June 23, 2006Publication date: June 28, 2007Applicant: Spherics, Inc.Inventors: Avinash Nangia, Jules Jacob, Peyman Moslemy, Daya Verma, Dinesh Haswani
-
Publication number: 20070003621Abstract: The invention relates to the improvement in the treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions and dosage forms. Another aspect of the invention relates to methods of treatment, comprising administering the drug composition and dosage form to an individual.Type: ApplicationFiled: June 23, 2006Publication date: January 4, 2007Applicant: Spherics, Inc.Inventors: Avinash Nangia, Jules Jacob, James Yeh, Peyman Moslemy, Daya Verma, Dinesh Haswani, Ze'ev Shaked
-
Publication number: 20040220081Abstract: Bioactive agents may be reproducibly converted into particles having diameters in the range of about 5 to about 2000 nanometers (nm). Conversion is accomplished by dissolving the bioactive agent in a solvent for the bioactive agent, and rapidly altering the polarity of the solution to make it a non-solvent for the bioactive agent, for example by diluting the bioactive agent solution with an excess of a liquid that is a non-solvent for the bioactive agent but is miscible with the solvent. Precipitated bioactive agent nanoparticles are collected by centrifugation, filtration or lyophilization. The nanoparticles have a relatively narrow size distribution, and the average diameter can be controlled by choice of solvent and non-solvent. The nanoparticles are typically amorphous. A surfactant may be added to ensure dispersion of the particles when administered. In the preferred embodiment, the bioactive agent is a drug with low aqueous solubility.Type: ApplicationFiled: October 30, 2003Publication date: November 4, 2004Applicant: Spherics, Inc.Inventors: Mark R. Kreitz, Yong S. Jong, Edith Mathiowitz, David J. Enscore, Michael J. Bassett
-
Publication number: 20030147965Abstract: A process for preparing nanoparticles, microparticles and nanoencapsulated products using the PIN process is provided. The invention involves using additives to reduce the aggregation or coalescence of the PIN nanoparticles, microparticles, or nanoencapsulated products during their formation and collection and to facilitate the recovery of said nanoparticles, microparticles, or nanoencapsulated products.Type: ApplicationFiled: December 10, 2002Publication date: August 7, 2003Applicant: Spherics, Inc.Inventors: Michael Bassett, Jules Jacob, David Enscore